Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-na ïve metastatic castration-resistant prostate cancer in Japan

ConclusionsResults modeled herein suggest that the enzalutamide-first sequencing is more cost-effective than the abiraterone-first sequencing, but less cost-effective than docetaxel-first sequencing for chemotherapy-na ïve patients with metastatic castration-resistant prostate cancer.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research